GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Nurix Therapeutics
Nurix Therapeutics is a biotech company pioneering targeted protein degradation. Its stock price represents a venture bet on a revolutionary new treatment technology. The chart reflects high volatility and dependence on lab news.
Share prices of companies in the market segment - Oncology targeted therapy
Nurix Therapeutics is a biopharmaceutical company developing drugs that modulate the ubiquitin-proteasome system for the treatment of cancer. We have classified it as a "Targeted Oncology" company. The chart below shows how the market is evaluating this cutting-edge scientific approach to cancer treatment.
Broad Market Index - GURU.Markets
Nurix Therapeutics is a biopharmaceutical company developing drugs that modulate the ubiquitin-proteasome system for the treatment of cancer. Its cutting-edge approach makes it a component of the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
NRIX - Daily change in the company's share price Nurix Therapeutics
Shares of Nurix Therapeutics, which focuses on targeted therapies, are highly volatile. change_co tracks investor reactions to clinical trial news. This metric is the basis for advanced biotech risk analysis formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Nurix Therapeutics, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with NRIX's performance, which hinges on the results of clinical trials for its protein degradation platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Nurix is a biopharmaceutical company, a pioneer in the field of targeted protein cleavage. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Nurix's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Nurix Therapeutics
Nurix is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Nurix Therapeutics, Inc. is a biotech company pioneering the development of a new class of drugs that exploit protein degradation mechanisms. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential and high risks of this cutting-edge field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nurix Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Nurix Therapeutics
A-Mark is a diversified company engaged in precious metals trading, lending, and storage. The monthly fluctuations on the chart reflect gold and silver prices, as well as trading volumes and demand for its financial services, which depend on investor interest in metals.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Nurix Therapeutics develops drugs that target proteins previously considered untreatable. This is a cutting-edge field in oncology. The biotech sector's dynamics reflect investors' overall appetite for risk and innovation. The chart below provides the backdrop against which Nurix demonstrates the potential of its scientific platform in the fight against cancer.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nurix Therapeutics, Inc. is a biopharmaceutical company pioneering targeted protein degradation for cancer treatment. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its cutting-edge scientific platform, which enables the "disabling" of cancer-causing proteins, impacts its valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Nurix Therapeutics
Nurix Therapeutics is a biotech company focused on a new class of drugs. Its weekly stock price is highly volatile, driven by news about the progress of its scientific platform and early clinical trial data.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Nurix Therapeutics is a biotech company. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart below shows how news about clinical trials of its innovative approach drives share price movements independent of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Nurix, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
NRIX - Market capitalization of the company Nurix Therapeutics
Nurix Therapeutics' market capitalization tells the story of a cutting-edge approach to treating cancer and immune diseases through the modulation of protein homeostasis. This biotech's stock price reflects investors' faith in its scientific platform. Its volatility reflects the market's reaction to early data that may confirm the potential of this new class of drugs.
NRIX - Share of the company's market capitalization Nurix Therapeutics within the market segment - Oncology targeted therapy
Nurix Therapeutics is a biotech company developing drugs that modulate the ubiquitin-proteasome system to kill cancer cells. Its market share reflects the potential of its cutting-edge scientific platform. The chart below shows the market weight assigned to this oncology innovator.
Market capitalization of the market segment - Oncology targeted therapy
Nurix Therapeutics develops drugs that modulate the ubiquitin-proteasome system for the treatment of cancer. The chart below shows the overall market capitalization of the oncology sector. It reflects interest in new drug mechanisms of action capable of attacking previously inaccessible targets.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph represents a new tactic in the fight against cancer. Nurix Therapeutics is developing drugs that don't destroy cancer proteins, but rather force the cell to recycle them. Its volatile line is a bet on this innovative approach. It's a visualization of the hope for a fundamentally new class of drugs.
Book value capitalization of the company, segment and market as a whole
NRIX - Book value capitalization of the company Nurix Therapeutics
Nurix Therapeutics' book value is determined by its scientific platform for discovering drugs that modulate protein degradation systems in the body and its financial reserves. This represents breakthrough scientific capital. The chart shows how the biotech company accumulates resources to fund its research in one of the hottest areas of oncology.
NRIX - Share of the company's book capitalization Nurix Therapeutics within the market segment - Oncology targeted therapy
Nurix Therapeutics is a biotech company that develops drugs that harness the body's natural defenses to destroy diseased proteins. Its assets are laboratories and research platforms. The chart shows that its value lies in innovation, not manufacturing capacity.
Market segment balance sheet capitalization - Oncology targeted therapy
Developing targeted therapies like Nurix's is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its drug discovery platform. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Nurix Therapeutics' assets are not factories, but a scientific platform and laboratories for developing drugs that utilize the body's natural system to "utilize" cancer-causing proteins. The book value reflects the material foundation of this innovative approach. The chart illustrates the scale of this biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Nurix Therapeutics
Nurix, which develops drugs that "destroy" cancer-causing proteins, is valued at a premium to its tangible assets. Investors are paying for its breakthrough scientific approach, which could open a new way to treat cancer.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Nurix Therapeutics is a company developing drugs that harness the body's natural system to destroy disease-causing proteins. Its high valuation on this chart reflects the breakthrough potential of this new technology in cancer treatment.
Market to book capitalization ratio for the market as a whole
Nurix Therapeutics is a biotech company working in the cutting-edge field of targeted protein degradation. This represents a new way to combat diseases previously considered untreatable. Its market valuation is a bet on the success of this revolutionary scientific platform. This metric reflects how the market views the potential of new modalities in medicine.
Debts of the company, segment and market as a whole
NRIX - Company debts Nurix Therapeutics
Nurix Therapeutics, a biotech company working in the field of protein degradation, funds its cutting-edge research through equity and strategic partnerships. This graph reflects the massive investment required to develop a completely new therapeutic modality, which requires a long-term financial horizon.
Market segment debts - Oncology targeted therapy
Nurix Therapeutics is a clinical-stage biotech company developing a new class of drugs that utilize the body's natural system to destroy disease-causing proteins. This cutting-edge approach requires significant investment in R&D. The chart below shows how the company is funding its research to combat cancer and inflammatory diseases.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Nurix Therapeutics
Nurix Therapeutics develops small molecules that harness the body's natural defenses to destroy cancer-causing proteins. This is a cutting-edge and highly capital-intensive approach in oncology. This chart illustrates the company's reliance on debt to fund its innovative, yet high-risk, research and clinical trials.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Nurix Therapeutics is a biopharmaceutical company working in the field of targeted protein degradation, a new approach to cancer treatment. It's a cutting-edge but risky field. This chart shows how the company finances its research and development, comparing its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Nurix Therapeutics develops drugs that utilize the body's natural system to destroy disease-causing proteins. This is a cutting-edge field that requires significant R&D investment. How heavily does the company rely on debt? This graph of total debt in the economy helps assess the riskiness of its biotech financial model.
P/E of the company, segment and market as a whole
P/E - Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company developing drugs that harness the body's natural system to break down disease-causing proteins. This chart demonstrates the company's high praise for its innovative approach. Investors are betting that this technology will lead to new cancer treatments.
P/E of the market segment - Oncology targeted therapy
Nurix Therapeutics is a biopharmaceutical company specializing in the development of small-molecule drugs that utilize or modulate the ubiquitin-proteasome system for the treatment of cancer and immune disorders. This chart shows the average valuation for the sector, helping to understand how the market views this cutting-edge scientific approach.
P/E of the market as a whole
Nurix Therapeutics is a biotech company working in the cutting-edge field of protein degradation to create new cancer drugs. This is a highly speculative, yet promising, field. Is the company's valuation in a world of scientific discovery, or is the overall market appetite for risk, visible in this chart, driving capital flows into such bold ideas?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company developing drugs that harness the body's natural defenses to destroy disease-causing proteins. This chart shows market expectations regarding the breakthrough potential of this technology. Future profits depend on the success of clinical trials and the commercialization of this new class of drugs.
%20P%2FE%20Nurix%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Nurix-Therapeutics&v=1772513914486 "Chart of the company's future (projected) P/E Nurix Therapeutics")
Future (projected) P/E of the market segment - Oncology targeted therapy
Nurix Therapeutics develops drugs that harness the body's natural system to break down disease-causing proteins. This is a cutting-edge approach to treating cancer and immune disorders. The chart shows forecasts for the oncology sector. This helps assess how highly the market values Nurix's innovative science and the potential of its DELigase platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772513914501 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Nurix Therapeutics, Inc. is a biotechnology company working in the field of targeted protein degradation for cancer treatment. This is a cutting-edge scientific approach. The company's valuation is a bet on future success. This chart shows how willing investors are to fund such high-risk, yet potentially breakthrough, scientific approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513914522 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Nurix Therapeutics
Nurix Therapeutics develops drugs that utilize the body's system to destroy cancer-causing proteins. This is a cutting-edge scientific approach. While in the clinical stage, the company incurs R&D losses. This graph illustrates the high cost of developing a new class of drugs and the long road to potential commercialization.
Profit of companies in the market segment - Oncology targeted therapy
Nurix Therapeutics develops drugs that harness the body's natural defenses to destroy disease-causing proteins. This chart, which charts profitability in the oncology sector, illustrates how science is seeking new approaches to cancer treatment. Their innovative platform targets previously considered druggable, opening new horizons in therapeutics.
Overall market profit
Nurix Therapeutics develops drugs that harness the body's natural system to destroy disease-causing proteins. This is a breakthrough approach to cancer treatment. Funding for such innovations depends on investors' risk appetite. Growing corporate profits, as shown in this chart, typically increases risk appetite, facilitating Nurix's access to capital.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Nurix Therapeutics
Nurix Therapeutics is a pioneer in developing drugs that harness the body's natural system to detoxify disease-causing proteins. This innovative approach is aimed at treating cancer. This graph represents analysts' expectations for the success of clinical trials and the potential of this breakthrough technology in oncology.
%20profit%20of%20the%20company%20Nurix%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Nurix-Therapeutics&v=1772513914629 "Graph of future (projected) profit of the company Nurix Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Nurix Therapeutics is a biopharmaceutical company developing drugs that modulate protein levels in cells to treat cancer and immune disorders. Its future depends on the success of its innovative platform. This biotech chart reflects the overall investor interest in breakthrough technologies and their willingness to fund early-stage companies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772513914633 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Nurix Therapeutics develops drugs that harness the body's natural system to destroy disease-causing proteins. This is cutting-edge science. The overall economic outlook presented here impacts the availability of venture capital and investor willingness to invest in long-term, capital-intensive biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513914637 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Nurix Therapeutics
Nurix Therapeutics is a company developing drugs that modulate the body's protein-utilization systems for the treatment of cancer. Despite the lack of profits, this chart is crucial. It shows how investors view its innovative scientific approach and future sales potential, placing their bets on a new class of oncology drugs.
P/S market segment - Oncology targeted therapy
Nurix Therapeutics is developing a new class of drugs that utilize the body's natural system to destroy disease-causing proteins. The company's valuation is based on the potential of this breakthrough technology. This chart shows the average valuation in the sector, allowing investors to understand the high expectations for Nurix's innovative approach to drug development.
P/S of the market as a whole
Nurix Therapeutics is a biopharmaceutical company developing drugs that harness the body's natural system to destroy disease-causing proteins. This chart, which reflects real-world business revenue estimates, shows that Nurix's valuation is a bet on its innovative approach to drug development, which can be applied to a wide range of diseases, including cancer.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biotech company focused on treating cancer by modulating the ubiquitin-proteasome system. This is at the cutting edge of science. This chart reflects investors' confidence in the potential of its scientific platform to create a new class of drugs that could generate billions in revenue in the future.
%20P%2FS%20Nurix%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Nurix-Therapeutics&v=1772513914806 "The graph of the company's future (projected) P/S Nurix Therapeutics")
Future (projected) P/S of the market segment - Oncology targeted therapy
Nurix Therapeutics is a biopharmaceutical company developing a new class of drugs that modulate protein levels in the body for the treatment of cancer and immune disorders. This chart shows the average future sales estimate for the biotech sector. It helps understand how the market values Nurix's advanced scientific platform for targeted therapy development.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772513914845 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Nurix Therapeutics develops drugs that utilize the body's natural system to eliminate diseased proteins that cause cancer. This indicator reflects the market's collective expectations. Nurix's approach opens new horizons in cancer treatment. Its research successes contribute to overall investor optimism regarding future medical breakthroughs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513914878 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Nurix Therapeutics
This chart shows the revenue of Nurix Therapeutics, a clinical-stage biopharmaceutical company developing drugs that harness the body's own systems to destroy cancer-causing proteins. Its revenue is generated through strategic alliances with major pharmaceutical companies, reflecting progress in commercializing its cutting-edge scientific platform.
Sales of companies in the market segment - Oncology targeted therapy
Nurix Therapeutics is a biopharmaceutical company developing a new class of drugs that utilize the body's natural system to destroy disease-causing proteins. This chart illustrates the growth of the targeted oncology market. This innovative approach can be applied to targets previously considered "untreatable," opening new horizons in cancer treatment.
Overall market sales
Nurix Therapeutics is a biopharmaceutical company focused on developing targeted therapies. Its growth depends on successful clinical trials and partnerships. The overall economic situation, shown in this chart, impacts the availability of capital for funding long-term and risky oncology projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Nurix Therapeutics
Nurix Therapeutics develops drugs that utilize the body's natural system to destroy cancer-causing proteins. Future revenue depends on the success of this innovative technology. The chart reflects analyst expectations for the commercialization of this new class of drugs.
%20sales%20of%20the%20company%20Nurix%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Nurix-Therapeutics&v=1772513915169 "Schedule of future (projected) sales of the company Nurix Therapeutics")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Nurix Therapeutics is developing a new class of drugs that work by modulating the ubiquitin-proteasome system to destroy or increase levels of disease-causing proteins. This cutting-edge approach is being applied in oncology and immunology. This oncology market forecast reflects the potential that breakthrough technologies like Nurix's can unlock.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772513915210 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
Nurix Therapeutics develops drugs that harness the body's natural defenses to destroy cancer-causing proteins. This is a cutting-edge approach in oncology. The company's funding depends on investors' risk appetite and belief in new scientific paradigms. This chart illustrates the overall investment climate, and Nurix's research progress is an indicator of the future development of targeted therapies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513915263 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Nurix Therapeutics
Nurix Therapeutics is a biotech company developing drugs that harness the body's natural defenses to destroy disease-causing proteins. Being in the clinical stage, it incurs significant research expenses. This chart shows its net losses—investments in innovative science aimed at creating a new class of drugs.
Market segment marginality - Oncology targeted therapy
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing a new class of drugs that utilize the body's natural system to break down disease-causing proteins. Profitability is a long-term goal. This chart reflects investment in their cutting-edge scientific platform. Investors evaluate its potential for creating breakthrough drugs.
Market marginality as a whole
Nurix Therapeutics is a biotech company developing drugs that harness the body's natural defenses to destroy proteins that cause diseases, particularly cancer. It's a pioneering approach. This overall profitability curve is irrelevant to them. Their future depends on the success of their scientific platform and the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Nurix Therapeutics
Nurix Therapeutics is a biotechnology company developing drugs that modulate cellular protein recycling systems. Its team consists of scientists and drug development specialists. The growth on this chart directly reflects the progress of its innovative platform and the progress of its clinical candidates.
Share of the company's employees Nurix Therapeutics within the market segment - Oncology targeted therapy
Nurix Therapeutics is a pioneer in targeted protein degradation—a new approach to treating cancer and other diseases. This chart shows the percentage of unique talent the company is attracting in this cutting-edge field of biotechnology. This growth reflects progress in developing a new class of drugs and the expansion of its scientific team.
Number of employees in the market segment - Oncology targeted therapy
Nurix Therapeutics, Inc. is a biopharmaceutical company focused on developing small-molecule drugs that modulate the body's ubiquitin-proteasome system. This chart illustrates the dynamics of employment in the cutting-edge field of targeted therapy. The growing number of researchers here signals progress in developing a new class of drugs for the treatment of cancer and immune disorders.
Number of employees in the market as a whole
Nurix Therapeutics is developing a new class of drugs that utilize the body's natural system to destroy disease-causing proteins. This approach, known as protein degradation, opens up new possibilities in cancer treatment. This chart shows how breakthrough scientific concepts are creating new areas of pharmaceutical development and high-tech jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Nurix Therapeutics (NRIX)
Nurix Therapeutics is a biotech company specializing in protein degradation-based therapies. This chart represents a pure intellectual capital valuation. The market values the potential of its unique scientific platform, not its staff. The chart shows the high future value investors are placing on this technology per scientist.
%20of%20the%20company%20Nurix%20Therapeutics%20(NRIX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Nurix-Therapeutics-NRIX&v=1772513915630 "Chart of market capitalization per employee (in thousands of dollars) of the company Nurix Therapeutics (NRIX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Nurix Therapeutics is a biotech company developing drugs that harness the body's natural defenses to destroy disease-causing proteins. Its valuation is based on its unique scientific platform. This chart demonstrates its high valuation of its advanced technologies per scientist.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772513915687 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Nurix Therapeutics is a biotech company developing drugs that utilize the body's own system to break down disease-causing proteins. This chart reflects the valuation of its cutting-edge scientific concept. The company's entire value is derived from its intellectual capital. This metric demonstrates the value the market places on the work of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513915731 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Nurix Therapeutics (NRIX)
Nurix Therapeutics is a clinical-stage biotech company specializing in a new class of drugs that utilize the body's waste disposal system (the proteasome) to destroy cancer-causing proteins. This is R&D. This chart shows capital burn: the amount the company spends on each scientist during expensive clinical trials.
%20Chart%20Nurix%20Therapeutics%20(NRIX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Nurix-Therapeutics-NRIX&v=1772513915738 "Company Profit Per Employee (in thousands of dollars) Chart Nurix Therapeutics (NRIX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Nurix Therapeutics (NRIX) is a clinical-stage biotech company developing drugs that "manage" protein degradation in cells. This is at the cutting edge of science. This metric (loss per employee) reflects the high cost of R&D for this new drug platform.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772513915835 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Nurix Therapeutics is a clinical-stage biotech company specializing in a novel method (protein degradation) for cancer treatment. It's an R&D company. The company is not profitable. This chart shows the company's capital burn rate: the operating loss per team of scientists developing this breakthrough technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513915884 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Nurix Therapeutics (NRIX)
Nurix Therapeutics is a biopharmaceutical company developing drugs that modulate protein levels in cells. This chart reflects the progress of monetizing its cutting-edge scientific platform. Revenue growth at this stage is likely due to upfront payments from major pharmaceutical industry partners who believe in its technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Nurix-Therapeutics-NRIX&v=1772513915934 "Sales chart per company employee Nurix Therapeutics (NRIX)")
Sales per employee in the market segment - Oncology targeted therapy
Nurix Therapeutics (NRIX) is a leader in protein degradation, a new approach to cancer treatment. This chart shows how productive their research team is. It measures revenue (likely from partnerships with big pharma) per researcher, comparing them to other companies in the targeted therapy segment.
Sales per employee for the market as a whole
Nurix Therapeutics (NRIX) is a clinical-stage biotech company specializing in a new class of drugs that utilize the protein degradation system. The company has no commercial revenue yet. This chart illustrates a typical situation for an R&D company: its entire scientific staff is focused on development and testing, generating data rather than revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Nurix Therapeutics (NRIX)
Nurix Therapeutics is a biotech company working in the field of protein degradation inhibitors (PROTACs), a novel approach to cancer treatment. This is a cutting-edge but highly competitive field. The bearish sentiment shown in this chart reflects investor skepticism about whether Nurix can outperform competitors and prove the safety of its platform.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Nurix-Therapeutics-NRIX&v=1772513916083 "Short Shares Chart for the Company Nurix Therapeutics (NRIX)")
Shares shorted by market segment - Oncology targeted therapy
Nurix Therapeutics is a biotech company developing drugs that "destroy" cancer-causing proteins (DELigase technology). This indicator measures pessimism. "Shorts" here represent a bet that their complex scientific platform will not prove safe or effective in the clinic.
Shares shorted by the overall market
Nurix Therapeutics is a biotech company working on a new class of drugs (PROTACs) targeting cancer-causing proteins. This is cutting-edge, but still very early science. When this chart shows rising general fear, investors are unwilling to fund scientific experiments. For NRIX, market pessimism is a threat to capital availability.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Nurix Therapeutics (NRIX)
Nurix Therapeutics (NRIX) is a biotech company working in the field of "protein degradation." They create small molecules that "teach" cells to destroy cancer-causing proteins. This chart measures hype. It shows "overheated" (above 70) during positive clinical trial data or "oversold" (below 30) during periods of anticipation and high uncertainty.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Nurix-Therapeutics-NRIX&v=1772513916142 "RSI 14 indicator chart for the company's stock Nurix Therapeutics (NRIX)")
RSI 14 Market Segment - Oncology targeted therapy
Nurix (NRIX) is a biotech company working on "protein degradation" (PROTAC). Their therapy doesn't "block" disease, but "destroys" its cause (especially in oncology). RSI_14_Seg for "Oncology" (biotech) reflects the overall sentiment. It helps us understand: is NRIX's volatility a sign of their breakthrough platform or just general hype?
RSI 14 for the overall market
Nurix (NRIX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NRIX (Nurix Therapeutics)
Nurix Therapeutics is a pioneer in targeted protein degradation (TPD). Their DELigase platform allows them to "tag" cancer-causing proteins for destruction. This chart shows the analysts' average 12-month forecast, representing their collective bet that this cutting-edge science will lead to the development of effective drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NRIX-Nurix-Therapeutics&v=1772513916233 "A chart showing analyst consensus forecasts for the expected stock price. NRIX (Nurix Therapeutics)")
The difference between the consensus estimate and the actual stock price NRIX (Nurix Therapeutics)
Nurix (NRIX) is a biotech company, a leader in protein degradation (PROTAC). Instead of blocking a bad protein (like in cancer), their DELigase technology helps the body destroy it. This is an R&D bet. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in this cutting-edge science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NRIX-Nurix-Therapeutics&v=1772513916267 "A chart showing the difference between the consensus forecast and the actual stock price. NRIX (Nurix Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Nurix Therapeutics (NRIX) is a biotech company pioneering "protein degradation"—a new cancer treatment that destroys, rather than blocks, harmful proteins. This chart shows the overall expectations for the targeted oncology sector, reflecting experts' confidence in this cutting-edge treatment technology.
Analysts' consensus forecast for the overall market share price
Nurix Therapeutics (NRIX) is an R&D biotech focused on a new protein-degrading technology (PROTAC) for cancer treatment. This chart, reflecting expert expectations, reflects their risk appetite. If the market is pessimistic, investors are unwilling to fund long-term research projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Nurix Therapeutics
Nurix is a new approach to cancer. They're a biotech company that's a leader in targeted protein degradation—essentially, they don't block the harmful protein, but destroy it. This chart is a clear indicator of their breakthrough science. It likely aggregates their clinical trial data and market confidence that their platform (DELigase) will become a new pillar in oncology.
AKIMA Market Segment Index - Oncology targeted therapy
Nurix (NRIX) is a biotech pioneer in protein degradation (like Kymera); the company develops innovative drugs (PROTACs/DELigase) that destroy, rather than block, cancer-causing proteins. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this breakthrough (PROTAC) R&D platform (NRIX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Nurix Therapeutics is a biotech company specializing in protein modulation (degradation and inhibition) for cancer treatment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific story with big pharma partnerships compares to overall economic trends.
